Cabaletta To Meet FDA By 2025 For Systemic Sclerosis Drug Trial

 Shares of Caballeta Bio Inc 

CABA+34.9%

+ Free Alerts

 rose by 24.38% to $3.01 apiece on Wednesday and advanced by 4.65% to $3.15 per share in after-hours trading, following an update on their Systemic Sclerosis drug trial.

What Happened: The company anticipates meeting the U.S. Food and Drug Administration in 2025 to discuss potential registrational trial designs, as per a statement by DelveInsight Business Research.

The report highlighted that Caballeta showcased positive clinical safety and efficacy data presented at the American College of Rheumatology Convergence 2024. The Systemic Sclerosis drug trial is ongoing with 16 patients with 10 patients dosed as of Nov. 12, 2024.

 The shares rose over the $3 per share mark for the first time on Wednesday in the last two weeks since Nov. 15. Also, the shares rose the most over 24% in a single day for the first time in two years since Dec. 14, 2022.

Cabaletta Bio is dedicated to developing engineered T-cell therapies to offer lasting, potentially curative treatments for autoimmune diseases. Their CABA platform includes both chimeric antigen receptor T cells and their proprietary chimeric autoantibody receptor T cells, designed to target autoimmune conditions.

https://www.benzinga.com/markets/equities/24/11/42229129/caballeta-bio-shares-surge-the-most-in-23-months-in-a-single-day-as-it-unveils-plan-to-meet-fda-by-2025-for-systemic-sclerosis-drug-trial